治疗转移性耐去势前列腺癌新药的最佳排序：是梦想还是现实？

Title:Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?

Volume: 17 Issue: 11

Author(s): Orazio Caffo, Andrea Lunardi, Chiara Trentin, Francesca Maines, Antonello Veccia, Enzo Galligioni

Affiliation:

关键词: 耐去势前列腺癌，序列，一线药物，二线药物，多烯紫杉醇，醋酸阿比特龙，cabazitaxel， enzalutamide

摘要: The availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidence of possible cross-resistance has reinforced the debate concerning the best sequence to use in order to maximise the benefit. Furthermore, the situation is further complicated by the possibility of administering new hormonal agents to chemotherapy-naïve patients, and novel chemotherapeutic agents to hormone-sensitive patients. This article critically reviews the available data concerning the sequential use of new drugs, and discusses the real evidence concerning their optimal positioning in the therapeutic strategy of metastatic castration-resistant prostate cancer.

Cite this article as:

Orazio Caffo, Andrea Lunardi, Chiara Trentin, Francesca Maines, Antonello Veccia, Enzo Galligioni , Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?, Current Drug Targets 2016; 17 (11) . https://dx.doi.org/10.2174/1389450117666160101121317